Growth Metrics

Adma Biologics (ADMA) Return on Capital Employed (2017 - 2025)

Historic Return on Capital Employed for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to 0.33%.

  • Adma Biologics' Return on Capital Employed fell 100.0% to 0.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.33%, marking a year-over-year decrease of 100.0%. This contributed to the annual value of 0.39% for FY2024, which is 3200.0% up from last year.
  • Latest data reveals that Adma Biologics reported Return on Capital Employed of 0.33% as of Q3 2025, which was down 100.0% from 0.34% recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' Return on Capital Employed peaked at 0.36% during Q4 2024, and registered a low of 0.32% during Q1 2021.
  • For the 5-year period, Adma Biologics' Return on Capital Employed averaged around 0.01%, with its median value being 0.06% (2023).
  • Per our database at Business Quant, Adma Biologics' Return on Capital Employed soared by 3300bps in 2024 and then crashed by -100bps in 2025.
  • Adma Biologics' Return on Capital Employed (Quarter) stood at 0.26% in 2021, then skyrocketed by 46bps to 0.14% in 2022, then skyrocketed by 154bps to 0.07% in 2023, then surged by 384bps to 0.36% in 2024, then dropped by -9bps to 0.33% in 2025.
  • Its Return on Capital Employed was 0.33% in Q3 2025, compared to 0.34% in Q2 2025 and 0.34% in Q1 2025.